人细胞系生物人工肝支持系统治疗慢加急性肝衰竭患者的初步研究

目的利用自行构建的混合生物人工肝支持系统,探讨其治疗肝衰竭患者的安全性和有效性。方法采用转染人肝再生增强因子（hALR）的HepG2细胞为生物材料构建生物反应器,利用慢加急性肝衰竭患者作为治疗对象,随机分组进行混合生物人工肝治疗及普通血浆置换治疗。结果治疗组6例患者中,4例经住院治疗1个月后临床好转出院,1例在治疗结束20d后因肝性脑病死亡,1例出院后1个月因肝肾综合征死亡,1例在恢复后1年因消化道出血死亡。对照组6例患者中存活2例,1例肝移植,3例因肝衰竭死亡。结论自行构建的混合生物人工肝支持系统功能良好,初步论证有一定的安全性和有效性。

Clinical study on hybrid bioartificial liver supporting system for acute on chronic liver failure patients

Objective To construct an hybrid bioartificial liver supporting system, and observe its effectiveness and safety on patients with acute on chronic liver failure. Methods Hybrid bioartificial liver supporting system （HBALSS） was constructed using bioreactor with HepG2 cells transfected with human augmenter of liver regeneration （hALR） gene. 12 acute on chronic liver failure patients were divided into 2 groups randomly. The treatment group was treated with the hybrid bioartificial liver support system. The group underwent plasma exchange was used as control. Results In the treatment group, four patients recovered, one patient died of hepatic encephalopathy, one patient died of hepatorenal syndrome, one patient recovered, but died of gastrointestnal bleeding after 1 year. In control group, two patients recovered, one patient underwent orthotropic liver transplantation, and three patients died of liver failure. Conclusion The hybrid bioartificial liver supporting system with HepG2 cell line was established successfully and have certain safety and effectiveness on acute on chronic liver failure patients.